Company / SG&A Expense
Mereo BioPharma Group plc SG&A Expense History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$23.0M
FY2025
5-year range
$18.4M / $26.4M
FY2023-FY2025
Trend
-13.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $18M to $23M over the past 2 years.
Based on SEC 10-K filings.
$23M in FY2025.
Increased from $18M to $23M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, sg&a expense decreased 13.0% year-over-year.
Company context
Key Data Points
- Altman Z-Score -7.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $23.0M | -13.0% |
| FY2024 | $26.4M | +43.5% |
| FY2023 | $18.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 27, 2026